Atharva Karulkar

About Atharva Karulkar

Atharva Karulkar, With an exceptional h-index of 7 and a recent h-index of 7 (since 2020), a distinguished researcher at Indian Institute of Technology Bombay, specializes in the field of Immunology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Evaluating the Safety of HCAR19 (Now Actalycabtagene Autoleucel-Actaly-Cel™), a Novel Humanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and …

Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel: Potential Impact on Access and Feasibility

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Phase I trial of humanized CD19 CART-cell therapy developed in India: safe, active and feasible for outpatient therapy

Making anti-CD19 CAR-T cell therapy accessible and affordable: first-in-human phase I clinical trial experience from India

Transcriptional Fluctuations Govern the Serum-Dependent Cell Cycle Duration Heterogeneities in Mammalian Cells

Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds

Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation

Atharva Karulkar Information

University

Position

___

Citations(all)

174

Citations(since 2020)

173

Cited By

37

hIndex(all)

7

hIndex(since 2020)

7

i10Index(all)

7

i10Index(since 2020)

7

Email

University Profile Page

Google Scholar

Atharva Karulkar Skills & Research Interests

Immunology

Top articles of Atharva Karulkar

Evaluating the Safety of HCAR19 (Now Actalycabtagene Autoleucel-Actaly-Cel™), a Novel Humanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and …

Blood

2023/12/1

Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel: Potential Impact on Access and Feasibility

Blood

2023/11/28

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Blood

2023/11/28

Phase I trial of humanized CD19 CART-cell therapy developed in India: safe, active and feasible for outpatient therapy

Blood

2022/11/15

Making anti-CD19 CAR-T cell therapy accessible and affordable: first-in-human phase I clinical trial experience from India

Blood

2022/11/15

Transcriptional Fluctuations Govern the Serum-Dependent Cell Cycle Duration Heterogeneities in Mammalian Cells

ACS Synthetic Biology

2022/11/3

Atharva Karulkar
Atharva Karulkar

H-Index: 3

Rahul Purwar
Rahul Purwar

H-Index: 10

Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds

2022/10/21

Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation

2022/5/23

IL-9 Abrogates the metastatic potential of breast cancer by controlling extracellular matrix remodeling and cellular contractility

The Journal of Immunology

2021/6/1

Robust antitumor activity and low cytokine production by novel humanized anti-CD19 CAR T cells

Molecular Cancer Therapeutics

2021/5/1

889 Interleukin-9 promotes malignant T cell survival by inhibiting oxidative stress and lactic acidosis in cutaneous T cell lymphoma

Journal of Investigative Dermatology

2020/7/1

The Th9 axis reduces the oxidative stress and promotes the survival of malignant T cells in cutaneous T-cell lymphoma patients

Molecular Cancer Research

2020/4/1

See List of Professors in Atharva Karulkar University(Indian Institute of Technology Bombay)